NCT02746783View on ClinicalTrials.gov

Immunogenicity and Safety of the Seasonal Flu Vaccine in Elderly and in SOT Recipients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

Single dose MUTAGRIP® influenza vaccine

All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.

DRUG

Double dose of MUTAGRIP® influenza vaccine

All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.

Trial Locations (1)

1011

Vaccine and Immunotherapy Center (VIC) of the Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

All Listed Sponsors
lead

University of Lausanne Hospitals

OTHER

NCT02746783 - Immunogenicity and Safety of the Seasonal Flu Vaccine in Elderly and in SOT Recipients | Biotech Hunter | Biotech Hunter